Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C

Special oncogenic mutations in the RAS proteins lead to the aberrant activation of RAS and its downstream signaling pathways. AMG510, the first approval drug for KRAS, covalently binds to the mutated cysteine 12 of KRASG12C protein and has shown promising antitumor activity in clinical trials. Recen...

Full description

Bibliographic Details
Main Authors: Haiming Zhuang, Jigang Fan, Mingyu Li, Hao Zhang, Xiuyan Yang, Ligen Lin, Shaoyong Lu, Qing Wang, Yaqin Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
KRAS
G12C
molecular dynamics simulations
AMG510
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.915512/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.915512/full

Similar Items